PRECLINICAL IN VITRO AND IN VIVO PROFILE OF PXT3003, A NEW PROMISING THERAPEUTIC CANDIDATE FOR CMT1A

被引：0
|
作者：
Chumakov, I [1 ]
Nabirotchkin, S. [1 ]
Milet, A. [1 ]
Cholet, N. [1 ]
Primas, G. [1 ]
Graudens, E. [1 ]
Bertrand, V [1 ]
Mandel, J. [1 ]
Pereira, Y. [1 ]
Nave, K-A [2 ]
Guerassimenko, O. [1 ]
Vial, E. [1 ]
Guedj, M. [1 ]
Cohen, D. [1 ]
机构：
[1] Pharnext, Issy Les Moulineaux, France
[2] Max Planck Inst, Gottingen, Germany
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2013年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [31] Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis
    Huang, Zhenhua
    Li, Heran
    Zhang, Qian
    Tan, Xiaojuan
    Lu, Fangzheng
    Liu, Hongzhuo
    Li, Sanming
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4319 - 4328
  • [32] Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study
    Viol, F.
    Amin, T.
    Sipos, B.
    Fruendt, T.
    Smolkova, B.
    Sainz, Jr B.
    Earl, J.
    Niessen, A.
    Izbicki, J.
    Hackert, T.
    Huber, S.
    Schrader, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 55 - 55
  • [33] Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation
    Abdelsamie, Ahmed S.
    Salah, Mohamed
    Siebenbuerger, Lorenz
    Hamed, Mostafa M.
    Boerger, Carsten
    van Koppen, Chris J.
    Frotscher, Martin
    Hartmann, Rolf W.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 178 : 93 - 107
  • [34] FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma
    Liu, Qing
    Alinari, Lapo
    Chen, Ching-Shih
    Yan, Fengting
    Dalton, James T.
    Lapalombella, Rosa
    Zhang, Xiaoli
    Mani, Rajeswaran
    Lin, Teresa
    Byrd, John C.
    Baiocchi, Robert A.
    Muthusamy, Natarajan
    CLINICAL CANCER RESEARCH, 2010, 16 (12) : 3182 - 3192
  • [35] PRECLINICAL DEVELOPMENT OF ALX-0061, AN ANTI-IL-6R NANOBODY® FOR THERAPEUTIC USE IN RHEUMATOID ARTHRITIS WITH A HIGH IN VITRO AFFINITY AND POTENCY AND A COMPETITIVE IN VIVO PHARMACOLOGICAL PROFILE
    Van Roy, M.
    Ulrichts, H.
    Rossenu, S.
    Jacobs, S.
    Poelmans, S.
    Verheyden, G.
    Baumeister, J.
    Holz, J. -B.
    INFLAMMATION RESEARCH, 2011, 60 : 112 - 112
  • [36] Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody® for therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
    Van Roy, Maarten
    Ulrichts, Hans
    Rossenu, Stefaan
    Jacobs, Sandy
    Poelmans, Sofie
    Verheyden, Gert
    Vierboom, Michel
    't Hart, Bert
    Baumeister, Judith
    Holz, Josefin-Beate
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S146 - S146
  • [37] Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models
    Kumar, Sujatha
    Ghosh, Srimoyee
    Sharma, Geeta
    Wang, Zebin
    Kehry, Marilyn R.
    Marino, Margaret H.
    Neben, Tamlyn Y.
    Lu, Sharon
    Luo, Shouqi
    Roberts, Simon
    Ramaswamy, Sridhar
    Danaee, Hadi
    Jenkins, David
    MABS, 2021, 13 (01)
  • [38] Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo study
    Xiao, Ting
    Ren, Shanfa
    Bao, Jiali
    Gao, Dandi
    Sun, Ronghao
    Gu, Xiaoting
    Gao, Jingjing
    Chen, Shanshan
    Jin, Jin
    Wei, Luqing
    Wu, Chunwa
    Yang, Cheng
    Yang, Guang
    Zhou, Honggang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 943
  • [39] Transient Receptor Potential Ankyrin 1 Receptor Activation In Vitro and In Vivo by Pro-tussive Agents: GRC 17536 as a Promising Anti-Tussive Therapeutic
    Mukhopadhyay, Indranil
    Kulkarni, Abhay
    Aranake, Sarika
    Karnik, Pallavi
    Shetty, Mahesh
    Thorat, Sandeep
    Ghosh, Indraneel
    Wale, Dinesh
    Bhosale, Vikram
    Khairatkar-Joshi, Neelima
    PLOS ONE, 2014, 9 (05):
  • [40] FT-1518, a new generation selective and potent mTORC1 and mTORC2 inhibitor: an in vitro and in vivo profile
    Mita, Alain C.
    Mita, Monica M.
    William, Anthony D.
    Pasha, Khalid
    Siddamadappa, Chandra
    Zikaras, Kevin
    Garzon, Felix T.
    CANCER RESEARCH, 2017, 77
12345